Latest News
The FDA has granted Fast Track designation to intravenous choline chloride (Protara Therapeutics), an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease.
The FDA has accepted for Priority Review the New Drug Application for lumasiran for the treatment of primary hyperoxaluria type 1.
Biochemical elevation of liver function and gastrointestinal (GI) symptoms were common in patients with COVID-19 at the time of hospital admission.
The use of thoracic epidural analgesia (TEA) in elective hepatopancreatobiliary (HPB) operations is associated with an increased risk of acquiring postoperative urinary tract infections (UTIs).
Patients with cirrhosis and acute kidney injury have longer hospital stays and higher mortality rates.
The combination resulted in durable response in many patients.
Study data supports the long-term efficacy and safety of besifovir dipivoxil maleate (BSV) for the treatment of chronic hepatitis B (CHB).
Women have a lower overall risk of acquiring nonalcoholic fatty liver disease (NAFLD) than men do, but a higher risk of advanced fibrosis if NAFLD status is confirmed.
The lack of standardized diet and exercise recommendations across NAFLD/NASH clinical trials has posed a significant challenge in understanding their impact.
Bi-dimensional shear wave elastography (2D-SWE) and conventional vibration-controlled transient elastography (VCTE) produced comparable measurements.
Patients using statins had a lower risk for any acute liver injury outcome within 18 months compared with non-users, regardless of HIV and/or hepatitis C virus (HCV) status.
Researchers identified abdominal pain, low serum carbohydrate antigen (CA) 19.9 levels, and absence of mass on imaging as independent predictors of benign lesions in patients with proximal biliary strictures (PBS), as indicated by study data published in HPB. According to the researchers, the aforementioned risk factors may be used to differentiate benign lesions from perihilar…
Atezolizumab plus bevacizumab improves survival outcomes versus sorafenib in patients with unresectable hepatocellular carcinoma.
The U.S. Preventive Services Task Force recommends screening adolescents and adults at increased risk for hepatitis B virus infection.
The first guidelines for assessing the eligibility of patients with NASH for inclusion in clinical studies were released.
The persistence of hepatitis E virus (HEV) markers after acute self-limited hepatitis E was assessed and according to the data published in Journal of Viral Hepatitis, the serologic test HEV-Ag performed best overall.
The clinical burden associated with nonalcoholic fatty liver disease is high.
In parallel to the ongoing national opioid crisis, the incidence rate of infective endocarditis cases has increased markedly among people aged 18 to 29 years with hepatitis C virus infection and those with opioid use disorder.
Experts proposed new guidelines on the diagnosis of metabolic-associated fatty liver disease (MAFLD), formerly non-alcohol fatty liver disease (NAFLD).
Compared with all opioid prescriptions, a higher hydromorphone controlled-release dispensing rate was a strong predictor of hepatitis C virus incidence.
